Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Richard Axelrod

Cardiovascular Disease Sacramento, CA Medical Doctor

NPI 1437147923 CMS profile 291417

2800 L St, 6Th Floor, Sacramento, CA 95816

Open in the dashboard

General payments

$10,079

117 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Richard Axelrod of Sacramento, CA is reported in the CMS Open Payments database as having received $10,079 across 117 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,410 12
2024 General $1,443 15
2023 General $932 9
2022 General $1,771 18
2021 General $713 13
2020 General $661 12
2019 General $3,150 38

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Richard Axelrod
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Richard Axelrod were reported at $1,410. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Richard Axelrod Cardiovascular Disease median Middle half National median
2019 $3,150 $450 $127–$1,392 $163
2020 $661 $242 $77–$751 $114
2021 $713 $335 $101–$1,037 $132
2022 $1,771 $395 $121–$1,211 $149
2023 $932 $443 $136–$1,283 $160
2024 $1,443 $450 $136–$1,323 $164
2025 $1,410 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $1,030 15 payments
  2. Biotronik Inc. $863 14 payments
  3. E.R. Squibb & Sons, L.L.C. $728 7 payments
  4. Novo Nordisk Inc $671 6 payments
  5. Merck Sharp & Dohme Corporation $645 6 payments
  6. Janssen Pharmaceuticals, Inc $572 9 payments
  7. Pfizer Inc. $552 5 payments
  8. Medtronic, Inc. $469 3 payments
  9. Abiomed $464 6 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $379 4 payments
  11. Other $3,706 42 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,067 115 payments
  2. Education $12 2 payments
Products named General payments · program years 2019–2025
  1. LifeVest $1,030 15 payments
  2. XARELTO $572 9 payments
  3. CAMZYOS $506 5 payments
  4. VERQUVO $384 4 payments
  5. WINREVAIR $363 3 payments
  6. Ozempic $355 3 payments
  7. Impella $317 5 payments
  8. Barostim Neo System $301 4 payments
  9. Edwards SAPIEN 3 Transcatheter Heart Valve $263 2 payments
  10. Vascepa $259 4 payments
  11. Other $5,626 57 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 37 drugs

Part D claims

2,587

Median for Cardiac Surgery: 68

Drug cost

$620,442

Median for Cardiac Surgery: $445

Branded share of claims

21%

Median for Cardiac Surgery: 15.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 209 $320,764
Multaq Dronedarone Hcl Brand 64 $89,189
Xarelto Rivaroxaban Brand 58 $76,129
Entresto Sacubitril/Valsartan Brand 29 $30,818
Farxiga Dapagliflozin Propanediol Brand 35 $29,713
Repatha Sureclick Evolocumab Brand 17 $25,196
Vascepa Icosapent Ethyl Brand 11 $11,134
Metoprolol Succinate Generic 251 $4,277
Atorvastatin Calcium Generic 324 $3,901
Nitroglycerin Generic 19 $2,486

The 10 drugs with the highest cost, of 37 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 411 Part D prescribers listed as Cardiac Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 42 billing codes

Paid by Medicare

$169,720

Medicare's payments for the services billed

Medicare patients

821

Average age 77

Services billed

2,581

361 women, 460 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 54%
Arthritis 52%
Heart failure 45%
Atrial fibrillation 43%
Chronic kidney disease 42%
Diabetes 37%
COPD 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
WINREVAIR
  • Merck Sharp & Dohme Corporation $122
$122 — —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $116
$116 — —
Wegovy
  • Novo Nordisk Inc $104
$104 — —
VERQUVO
  • Merck Sharp & Dohme Corporation $102
$102 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $19
$19 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

117 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record